139. Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level Variation in Burden and Outcome in 156 US hospitals, 2000-2014
Session: Oral Abstract Session: The Cutting Edge in Antimicrobial Resistance Emergence Therapy
Thursday, October 5, 2017: 11:15 AM
Room: 01AB

Background: Discordance between In vitro susceptibility and empiric antibiotic therapy is inextricably linked to antibiotic resistance and decreased survival in bloodstream infections (BSI). However, its prevalence, patient- and hospital-level risk factors, and impact on outcome in a large cohort and across different pathogens remain unclear.

Methods: We examined in vitro susceptibility interpretations for bacterial BSI and corresponding antibiotic therapy among inpatient encounters across 156 hospitals from 2000-2014 in the Cerner Healthfacts database. Discordance was defined as nonsusceptibility to initial therapy administered from 2 days before pathogen isolation to 1 day before final susceptibility reporting. Discordance prevalence was compared across taxa; risk factors and its association with in-hospital mortality were evaluated by logistic regression. Adjusted odds ratios (aOR) were estimated for pathogen-, patient- and facility-level factors.

Results: Of 33,161 unique encounters with BSIs, 4,219 (13%) at 123 hospitals met criteria for discordant antibiotic therapy, ranging from 3% for pneumococci to 55% for E. faecium. Discordance was higher in recent years (2010-14 vs. 2005-09) and was associated with older age, lower baseline SOFA score, urinary (vs. abdominal) source and hospital-onset BSI, as well as ≥500-bed, Midwestern, non-teaching and rural hospitals. Discordant antibiotic therapy increased the risk of death [aOR=1.3 [95% CI 1.1-1.4]). Among gram negative taxa, discordant therapy increased risk of mortality associated with Enterobacteriaceae (aOR=1.3 [1.0-1.6]) and non-fermenters  (aOR=1.7 [1.1-2.5]). Among gram positive taxa, risk of mortality from discordant therapy was significantly higher for S. aureus (aOR=1.3 [1.1-1.6]) but unchanged for streptococcal or enterococcal BSIs.

Conclusion: The prevalence of discordant antibiotic therapy displayed extensive taxon-level variability and was associated with patient and institutional factors. Discordance detrimentally impacted survival in gram negative and S. aureus BSIs. Understanding reasons behind observed differences in discordance risk and their impact on outcomes could inform stewardship efforts and guidelines for empiric therapy in sepsis.

 

 

 

 

ID Week 2017 Abstract_Discordant_abx_therapy_bacteremia_Table1.tif

ID Week 2017 Abstract_Discordant_abx_therapy_bacteremia_Table2.tif

Sameer S. Kadri, MD, MS1, Yi Ling Lai, MPH2, Emily Ricotta, PhD, ScM2, Jeffrey Strich, MD3, Ahmed Babiker, MBBS4, John P. Dekker, M.D., Ph.D.5, Tara Palmore, MD6, Chanu Rhee, MD, MPH7, Michael Klompas, MD, MPH, FRCPC, FIDSA8, David C. Hooper, MD9, John H. Powers III, MD10, Robert L. Danner, MD1, Jennifer Adjemian, PhD2,11 and NIH Antimicrobial Resistance Outcomes Research Initiative (ARORI), (1)Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, (2)Epidemiology Unit, Division of Intramural Research, NIAID, NIH, Bethesda, MD, (3)Department of Internal Medicine, Georgetown University Hospital, Washington, DC, (4)Internal Medicine, Providence Hospital, Washington, DC, (5)Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD, (6)Hospital Epidemiology Service, NIH Clinical Center, NIH, Bethesda, MD, (7)Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, (8)Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, (9)Harvard Medical School, Boston, MA, (10)Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, (11)United States Public Health Service, Commissioned Corps, Rockville, MD

Disclosures:

S. S. Kadri, None

Y. L. Lai, None

E. Ricotta, None

J. Strich, None

A. Babiker, None

J. P. Dekker, None

T. Palmore, None

C. Rhee, None

M. Klompas, None

D. C. Hooper, None

J. H. Powers III, None

R. L. Danner, None

J. Adjemian, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.